1. Home
  2. KPRX

KPRX

Kiora Pharmaceuticals Inc.

Logo Kiora Pharmaceuticals Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-19-2024 2:17pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Founded: N/A Country:
United States
United States
Employees: N/A City: ENCINITAS
Market Cap: 15.1M IPO Year: N/A
Target Price: $2.00 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.69 EPS Growth: N/A
52 Week Low/High: $0.46 - $5.25 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -85.37%

Share on Social Networks:

Latest Kiora Pharmaceuticals Inc. News

KPRX Breaking Stock News: Dive into KPRX Ticker-Specific Updates for Smart Investing

All KPRX News